- Home
- KALA vs INKT Comparison
KALA vs INKT Comparison
Compare KALA & INKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KALA
- INKT
- Stock Information
- Founded
- KALA 2009
- INKT 2017
- Country
- KALA United States
- INKT United States
- Employees
- KALA N/A
- INKT N/A
- Industry
- KALA Biotechnology: Pharmaceutical Preparations
- INKT Medicinal Chemicals and Botanical Products
- Sector
- KALA Health Care
- INKT Health Care
- Exchange
- KALA Nasdaq
- INKT Nasdaq
- Market Cap
- KALA 26.2M
- INKT 28.9M
- IPO Year
- KALA 2017
- INKT 2021
- Fundamental
- Price
- KALA $6.90
- INKT $7.73
- Analyst Decision
- KALA Strong Buy
- INKT Strong Buy
- Analyst Count
- KALA 3
- INKT 2
- Target Price
- KALA $14.00
- INKT $37.50
- AVG Volume (30 Days)
- KALA 117.3K
- INKT 14.8K
- Earning Date
- KALA 08-05-2025
- INKT 08-12-2025
- Dividend Yield
- KALA N/A
- INKT N/A
- EPS Growth
- KALA N/A
- INKT N/A
- EPS
- KALA N/A
- INKT N/A
- Revenue
- KALA N/A
- INKT N/A
- Revenue This Year
- KALA N/A
- INKT N/A
- Revenue Next Year
- KALA N/A
- INKT N/A
- P/E Ratio
- KALA N/A
- INKT N/A
- Revenue Growth
- KALA N/A
- INKT N/A
- 52 Week Low
- KALA $2.92
- INKT $4.56
- 52 Week High
- KALA $11.20
- INKT $13.79
- Technical
- Relative Strength Index (RSI)
- KALA 77.24
- INKT 57.39
- Support Level
- KALA $4.36
- INKT $6.80
- Resistance Level
- KALA $5.75
- INKT $7.88
- Average True Range (ATR)
- KALA 0.66
- INKT 0.40
- MACD
- KALA 0.20
- INKT 0.02
- Stochastic Oscillator
- KALA 96.85
- INKT 58.86
About KALA KALA BIO Inc.
Kala Bio Inc is a biopharmaceutical company. The company is a clinical-stage biopharmaceutical company dedicated to researching, developing, and commercializing therapies for rare and severe eye diseases. KALA'smain product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease.
About INKT MiNK Therapeutics Inc.
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company is advancing a pipeline of both native and next generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery.